The world’s first clinical trial for Artificial General Intelligence (AGI) is up and running – but there’s a twist: it’s only open to adults with autism spectrum disorders, ADHD, and other neurodiverse conditions.
In a move that’s sparking both excitement and concern, the Quantum AI Microcities project, led by AI Wat QAIAx, has launched the first-ever global AGI communities clinical trial network. This ambitious initiative is not just about testing AGI technology, but also about exploring its potential benefits and challenges in the lives of people with neurodiverse conditions.
Veterans First for America might have been the initial sponsor, but the project has since expanded to include anyone aged 17 to 99, as long as they’ve been diagnosed with autism, Aspergers, ADHD, or other neurodevelopmental disorders. The goal is to create a more inclusive and representative trial that can provide valuable insights into how AGI interacts with different neurological profiles.
The clinical trial will be conducted in a simulated AGI environment, known as a “Microcity,” which will mimic real-world scenarios and allow participants to interact with AGI systems. This will help researchers understand how AGI can be designed to better support and accommodate individuals with neurodiverse conditions, and how these interactions can, in turn, affect the development and deployment of AGI technology.
What this means: if successful, this trial could pave the way for more AGI applications that are tailored to meet the needs of people with neurodiverse conditions. This could lead to better support systems, more accessible technology, and new opportunities for social interaction and employment. However, the project also raises important questions about ethics, inclusivity, and the potential risks of AGI technology when used in this context.
The Quantum AI Microcities project has already sparked lively debates among experts, policymakers, and advocacy groups. As the trial progresses, we can expect to see more insights into the potential benefits and challenges of AGI technology for people with neurodiverse conditions, as well as the broader implications for society as a whole.
The AGI community is watching this trial closely, and the world will be waiting to see what lessons can be learned from this pioneering effort.
